Clinical Trial Update: Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the safety and efficacy of albumin interferon given every four weeks in patients with genotype 2/3 chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Albumin Interferon

Snippet

Sponsor: Novartis | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED